Drugs / Kylo-11
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06363851 | May 2024 → Jun 2025 | cardiovascular disorder | Kylonova (Xiamen) Biopharma co., LTD. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07327840 | Oct 2025 → Feb 2027 expected | inherited lipid metabolism disorder | Kylonova (Xiamen) Biopharma co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kylo-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06363851 ↗ |
| Route | Subcutaneous | “Single ascending doses of Kylo-11 administered subcutaneously (SC).” NCT06363851 ↗ |